Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
Dok-7 is required for formation of the Neuromuscular Junction[edit | edit source]
During development, the growing end of motor neuron axons secrete a protein called agrin. This protein binds to several receptors on the surface of skeletal muscle. The receptor which seems to be required for formation of the neuromuscular junction (NMJ) is called MuSK (Muscle specific kinase). MuSK is a receptor tyrosine kinase - meaning that it induces cellular signaling by causing the addition of phosphate molecules to particular tyrosines on itself, and on proteins which bind the cytoplasmic domain of the receptor.
Dok-7 signaling[edit | edit source]
The requirement for MuSK in the formation of the NMJ was primarily demonstrated by mouse "knockout" studies. In mice which are deficient for either agrin or MuSK, the neuromuscular junction does not form.
Upon activation by its ligand agrin, MuSK signals via the proteins called Dok-7 and rapsyn, to induce "clustering" of acetylcholine receptors (AChR). Cell signaling downstream of MuSK requires Dok-7. Mice which lack this protein fail to develop endplates. Further, forced expression of Dok-7 induces the tyrosine phosphorylation, and thus the activation of MuSK. Dok-7 interacts with MuSK by way of protein "domain" called a "PTB domain."
In addition to the AChR, MuSK, and Dok-7 other proteins are then gathered, to form the endplate to the neuromuscular junction. The nerve terminates onto the endplate, forming the neuromuscular junction - a structure which is required to transmit nerve impulses to the muscle, and thus initiating muscle contraction.
Congenital Myasthenia Syndrome[edit | edit source]
Homozygous mutation of Dok-7 is responsible for a form of congenital myasthenic syndrome (CMS) that is unique among disorders in this category because it affects muscles in the limbs and trunk but mostly spares the face, eyes, and functions of the mouth and pharnyx (chewing, swallowing and speech). Salbutamol can be effective in relieving CMS symptoms attributable to Dok-7 mutations.
References[edit | edit source]
- Valenzuela DM, Stitt TN, DiStefano PS, et al. (Sep 1995). Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 15 (3): 573–84.
- DeChiara TM, Bowen DC, Valenzuela DM, et al. (May 1996). The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85 (4): 501–12.
- Glass DJ, Bowen DC, Stitt TN, et al. (May 1996). Agrin acts via a MuSK receptor complex. Cell 85 (4): 513–23.
- Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (Mar 2001). Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 7 (3): 365–8.
- Strochlic L, Cartaud A, Cartaud J (Nov 2005). The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions. Bioessays 27 (11): 1129–35.
- Okada K, Inoue A, Okada M, et al. (Jun 2006). The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312 (5781): 1802–5.
- Palace J, Lashley D, Newsom-Davis J, et al. (Jun 2007). Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain 130 (Pt 6): 1507–15.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|